Thumbnail Image
Publication

Drug Pricing Investigation: Mallinckrodt--H.P. Acthar Gel

House Committee on Oversight and Reform
Abstract
The House Committee on Oversight and Reform investigated Mallinckrodt Pharmaceuticals' actions related to H.P. Acthar Gel, a drug approved in 1952 for rare infant seizure disorder and other conditions. Acthar, historically sold for less than $40 per vial, has seen an approximately 140,000% price increase over 68 years, with a typical vial now priced at $39,864. The report, based on over 140,000 pages of internal documents from 2014 to 2018, primarily examines Mallinckrodt's acquisition of Acthar and subsequent pricing practices for the medicine, shedding light on the significant price hike.
Date
2020-10-01
Document Type
House Staff Report
Serial Number
Document Length
50 pages
Congress
116
Show all metadata
Files
Thumbnail Image
2020-10-01_R-Drug_Pricing_Investigation-(Mallinckrodt-HP_Acthar_Gel)-116C.pdf
Adobe PDF, 2.83 MB
Thumbnail Image
2020-10-01_R-Mallinckrodt-HP_Acthar_Gel-(selected_docs)-116C.pdf
Adobe PDF, 4.56 MB
URI
https://hdl.handle.net/20.500.14300/1171
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Related Hearings
Press Releases and Contextual Information
Collections
House Oversight Committee